SHOCK HYPOVOLEMIQUE OF SEPTIC OR HAEMORRHAGIC ORIGIN
Conditions
Interventions
Trade Name: HyperHes®
Product Name: hyperHes®
Pharmaceutical Form: Solution for injection
INN or Proposed INN: hydroxyéthylamidon 200 000
Concentration unit: g/l gram(s)/litre
Concentration type: equa
Sponsors
Assistance Publique Hopitaux de marseille
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: PATIENTS PRESENTING A HYPOVOLEMIE AIGUE WHITIN THE FRAMEWORK OF A TOXIC SHOCK OR A HAEMORRHAGIC SHOCK Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Patient of less than 18 years Pregnancy Absence of assent Patient at the end of life evolved Cardiac insufficiency (NYHA III or IV) Allergy known about the hydroxyethylamidon Hypernatrémie = 150mmol / L
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Evaluation of the variation of the Blood pressure Averages according to the speed of drip.;Secondary Objective: ESTIMATE OF THE VARIATION OF the CARDIAC OUTPUT ACCORDING TO THE SPEED OF DRIP OF THE OXYGENATION BY CALCULATION OF the REPORT PAO2/FIO2 ESTIMATE OF THE NATREMIE;OF THE CHLOREMIE AND the ARTERIAL PH;Primary end point(s): The tested hypothesis is the absence of significant variations of the average blood pressure hanging and after the administration of HyperHES ® in the group with slow drip (30 minutes) with regard to the values of bases, and the existence of a significant decrease of the average blood pressure hanging in the group receiving HyperHES ® by fast drip (5 minutes) compared with the basic values and with the group with slow drip. | — |
Countries
France
Outcome results
None listed